Loading...
XKRX
005257
Market cap326mUSD
Oct 08, Last price  
18,000.00KRW
1D
-4.00%
1Q
1.29%
Jan 2017
-15.49%
Name

Green Cross Holdings

Chart & performance

D1W1MN
XKRX:005257 chart
P/E
—
P/S
0.33
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
7.35%
Revenues
2.45t
+11.19%
629,534,600,000533,618,697,000680,231,174,000832,291,097,000817,434,910,350855,344,622,740934,622,237,8301,043,840,314,4201,132,119,623,9101,353,893,060,7901,464,875,446,0901,547,971,214,0401,524,799,074,0001,719,325,650,0001,840,558,603,0002,079,559,971,0002,057,935,705,0002,204,855,223,0002,451,476,281,000
Net income
-69.51b
L
24,577,921,00021,360,397,00037,606,976,00067,522,188,00027,675,146,00061,546,845,80043,549,742,61056,760,788,98065,420,806,36047,176,642,04043,364,195,34018,466,539,830-30,476,552,000170,960,320,00055,269,749,00032,823,018,000-54,136,305,00024,025,032,000-69,512,977,000
CFO
24.30b
P
262,766,269,000167,466,117,000482,604,136,000355,618,664,000116,177,695,40036,796,180,23017,568,307,99054,542,863,2307,035,743,480-805,469,520144,482,443,82037,643,839,2907,650,392,00035,772,090,000103,769,151,00097,156,791,000-39,654,747,000-89,947,939,00024,299,847,000
Dividend
Mar 30, 2026300 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

GC Corp., formerly known as Green Cross Holdings Corporation, is a South Korean biotechnology company. It provides a range of products including prescription drugs, vaccines, and blood plasma derivatives, and also offers pharmaceutical logistics and cell therapy services.

Key people

Sang Seop Kim
Internal Auditor, Director · since 2024
Yong Jun Huh
Co-Chief Executive Officer, Director · since 2017
Yil Seop Huh
Chairman, Co-Chief Executive Officer · since 2017
Yong Tae Park
Vice Chairman · since 2010
Jun Ho Kang
Non-Executive Independent Director · since 2025
Seok Hwa Kim
Non-Executive Independent Director
URL
https://www.gccorp.com/
IPO date
Aug 28, 1978
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT